ResMed appoints new CPO, CMO, CRO; COO Douglas to retire Jan 1, 2024

RESMED INC

Rob Douglas, President & COO, retires Jan 1, 2024; transitions to special advisor to CEO immediately.
Justin Leong named Chief Product Officer, Katrin Pucknat as CMO, Mike Fliss as CRO, effective immediately.
Lucile Blaise moves from president sleep & respiratory care to SVP strategy & business development.
New operating model sets product-led, customer-centric, brand-enhanced focus to accelerate profitable growth.
Former CTO Urvashi Tyagi becomes special advisor to CPO through Jan 1, 2024; consulting through Dec 31, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert Douglas

special advisor to the CEO

RMD · RESMED INC

Effective: 2024-01-01
Filed: November 9, 2023, 6:59 PM ET

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

Role change

Robert Douglas

special advisor to the CEO

RMD · RESMED INC

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

Role change

Lucile Blaise

senior vice president, strategy & business development

RMD · RESMED INC

Effective: 2023-11-09
Filed: November 9, 2023, 6:59 PM ET

Lucile Blaise, our former president, sleep & respiratory care, will transition to a role as senior vice president, strategy & business development, reporting to our Chief Strategy Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Douglas retired as special advisor to the CEO at RESMED INC.

Action: retired
Role: special advisor to the CEO

Exact text from the filing

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Douglas changed role as special advisor to the CEO at RESMED INC.

Action: transitioned
Role: special advisor to the CEO

Exact text from the filing

On November 9, 2023, we announced that Robert Douglas, our chief operating officer and president, will transition to a role as special advisor to the CEO effective immediately and will retire, effective January 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lucile Blaise changed role as senior vice president, strategy & business development at RESMED INC.

Action: transitioned
Role: senior vice president, strategy & business development

Exact text from the filing

Lucile Blaise, our former president, sleep & respiratory care, will transition to a role as senior vice president, strategy & business development, reporting to our Chief Strategy Officer.

View on SEC.gov

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-23-274543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.